News
Serena Williams, Zepbound and Weight loss
Digest more
Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...
U.S. prices for obesity-treatment pills that Eli Lilly and Novo Nordisk aim to launch next year likely will be on par with ...
A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...
A new imaging approach reveals how dual agonist drugs like tirzepatide act on the pancreas and brain to regulate blood sugar and appetite.
GLP-1 drugs for diabetes and weight loss may influence patients’ cancer risk, usually lowering it but sometimes possibly ...
No one stays on top forever. It’s a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish ...
Viking Therapeutics (VKTX 5.71%) fell a whopping 39.2% from their previous close on Tuesday, Aug. 19. Investors were reacting ...
In the past couple years, demand has gone wild for drugs like Ozempic – and its cousins, Zepbound, Wegovy, and Mounjaro. For ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback